enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Why Y-mAbs Therapeutics Stock Got Mashed on Monday - AOL

   www.aol.com/why-y-mabs-therapeutics-stock...

   The company didn't quite meet expectations for either trailing results or full-year guidance.

3. Y-mAbs Reports Third Quarter 2024 Financial Results and ...

   lite.aol.com/tech/story/0022/20241108/9270001.htm

   NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results ...

4. Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion ... - AOL

   www.aol.com/news/y-mabs-ymab-stock-pre-152903776...

   Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

5. Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

   lite.aol.com/tech/story/0022/20241025/9261890.htm

   NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results ...

6. Analysts Slash Y-mAbs Therapeutics Price Targets As ... - AOL

   www.aol.com/news/analysts-slash-y-mabs...

   The analyst maintained the Buy rating on the stock. The analyst notes. On Friday, FDA's Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 that Y-mAbs Therapeutics Inc (NASDAQ: YMAB) did not ...

7. Correcting & Replacing – Y-mAbs Provides Strategic Business ...

   lite.aol.com/tech/story/0022/20250110/9329988.htm

   NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced strategic ...

8. How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do ... - AOL

   www.aol.com/news/much-y-mabs-therapeutics-inc...

   The big shareholder groups in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have power over the company. Institutions will...

9. Here's Why We're Watching Y-mAbs Therapeutics' (NASDAQ ... - AOL

   www.aol.com/news/heres-why-were-watching-y...

   For premium support please call: 800-290-4726 more ways to reach us